Renal Denervation for the Treatment of Hypertension

Published: August 05, 2024

  • Radiofrequency and ultrasound renal nerve denervation (RDN) are approved by the US Food and Drug Administration for the adjunctive treatment of hypertension (HTN) in patients for whom lifestyle and antihypertensive medications do not adequately control blood pressure (BP).
  • RDN has been proven effective in patients with mild, moderate, and resistant hypertension, with a BP-lowering efficacy of RDN comparable to that of an effective antihypertensive drug.
  • RDN therapy has a favorable safety profile with a very low incidence of major adverse events. Medium to longer-term safety data show no evidence of associated kidney dysfunction or new or worsening renal artery stenosis, but the continued collection of safety data is important.